|
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients Clinical research trials and A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients. A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients clinical trial. Test subjects typically receive the most expert healthcare available for their A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients  A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
For Condition: HIV Infections,Psoriasis
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.
Details:
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.) Documented HIV antibody (by federally licensed ELISA test) positive patients. Prior Medication: Allowed: - Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Presence of any active opportunistic infection. - Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma. - Known hypersensitivity to zidovudine (AZT). - Impaired renal function. - Significant hepatic dysfunction. Concurrent Medication: Excluded: Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical steroids (emollients used distal to the control lesions and antipruritic shampoos are admissible). Patients with the following are excluded: - Presence of any active opportunistic infection. - Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma. - Known hypersensitivity to zidovudine (AZT). - Impaired renal function. - Significant hepatic dysfunction. Prior Medication: Excluded: - Other antiretroviral agents (e.g., suramin, ribavirin, HPA-23, dideoxycytidine). - Excluded within 2 weeks of study entry: - Topical steroid, anthralin, or tar preparations. - Any other experimental therapy drugs which cause significant bone marrow suppression such as antifolates or pyrimethamine. - Cytolytic chemotherapy. - Drugs which cause significant nephrotoxicity or hepatotoxicity. - Rifampin or rifampin derivatives. - Excluded within 4 weeks of study entry: - Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. - Excluded within 8 weeks of study entry: - Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2.
Total Enrollment:
Location and Contact Information:
Glaxo Wellcome Inc
Research Triangle Park, North Carolina, 27709
United States
Additional Information:
Study ID Numbers: 014F; 16
Study Start Date:
Record last reviewed: September 1989
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002286
Other Hiv Infections Studies:
1. Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
2. Study of Topical Calcitriol or Oral Calcitriol in Patients with Psoriasis
3. Characterizing Serum Protein Patterns in Selected Skin Diseases
4. Scalp Psoriasis Treatment with a Fiber Optic Comb
5. Study of Psoriatic Arthritis
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
|
|
|
|
|
|
|
|
